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Abstract 
 
Stroke prevention is central to the management of patients with atrial fibrillation (AF). As 
effective stroke prophylaxis essentially requires oral anticoagulants (OAC) an understanding 
of the risks and benefits of OAC therapy is needed. While AF increases stroke risk 5-fold, this 
risk is not homogeneous.  Many stroke risk factors also confer an increased risk of bleeding.  
Various stroke and bleeding risk stratification schemes have been developed to help inform 
clinical decision making.  These scores were derived and validated in different study cohorts, 
ranging from highly selected clinical trial cohorts to ‘real world’ populations. Thus, their 
performance and classification accuracy varies depending on their derivation cohort(s). 
 
In the present review, we provide an overview of currently available stroke and bleeding risk 
stratification schemes. We particularly focus on the CHA2DS2-VASc and HAS-BLED schemes, 
as these are recommended by the latest European guidelines on AF management. Other risk 
stratification schemes (CHADS2, R2CHADS2, ATRIA, HEMORR2HAGES, QStroke, etc.) and their 
place in the decision-making are also considered. 
 
Key words:  atrial fibrillation, stroke, bleeding, risk assessment. 
  
Ре
по
зи
то
ри
й Г
рГ
М
У
 3
Introduction 
The increasing prevalence of atrial fibrillation (AF) brings high burden of arrhythmia-related 
complications among which stroke is the most disabling and associated with high mortality 
and morbidity.1,2  Stroke prevention is central to the management of patients with AF. As 
effective stroke prophylaxis essentially requires oral anticoagulants (OAC) an understanding 
of the risks and benefits of OAC therapy is needed.3,4  While AF increases stroke risk 5-fold, 
this risk is not homogeneous.  Many stroke risk factors also confer an increased risk of 
bleeding.  Various stroke and bleeding risk stratification schemes have been developed to 
help inform clinical decision making.  These scores were derived and validated in different 
study cohorts, ranging from highly selected clinical trial cohorts to ‘real world’ populations. 
Thus, their performance and classification accuracy varies depending on their derivation 
cohort(s).5 
 
In the present review article, we provide an overview and critique of currently available 
stroke and bleeding risk stratification schemes. We particularly focus on the CHA2DS2-VASc 
and HAS-BLED schemes, as these are recommended by the latest European guidelines on AF 
management.3,6 Other risk stratification schemes (CHADS2, R2CHADS2, ATRIA, 
HEMORR2HAGES, QStroke, etc) and their place in the decision-making are also considered. 
 
 
Stroke risk 
There are a large number of stroke risk factors identified among AF patients; hence, an 
individual patient’s risk will depend largely on the combination of risk factors rather than 
from simply being an ‘AF patient’. Permutations of these risk factors have been used to Ре
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formulate stroke risk stratification schemes, with the initial objective of identifying ‘high risk’ 
patients to be targeted for OAC using an ‘inconvenient’ drug, warfarin.7,8 
 
The derivation of stroke risk stratification schemes depends on identification of common risk 
factors, which – importantly – have been defined and recorded in derivation cohorts.  Some 
schemes are also simplistic in assuming each risk factor carries equal weight.  In addition, the 
significance of some risk factors can change with effective treatment, for example, blood 
pressure.  The (independent) impact of a particular stroke risk factor is also best tested in a 
non-anticoagulated cohort preferably from a ‘real world’ setting with a broad range of 
stroke risk, rather than a selected clinical trial cohort where intervention(s) may influence 
event rates. 
 
The Stroke Risk in Atrial Fibrillation Working Group identified common predictors of stroke in 
AF  from a systematic review of seven studies (Framingham Heart Study10, Stroke prevention 
in atrial fibrillation [SPAF]11, AF Investigators [AFI]12,13, AnTicoagulation and Risk factors In 
Atrial fibrillation [ATRIA]14  and others15,16).  This analysis found history of stroke or transient 
ischaemic attack (TIA, 2.5-fold higher risk),  as well as advanced age (1.5-fold higher risk with 
each 10 years), arterial hypertension(either history of hypertension or systolic blood 
pressure or systolic blood pressure >160 mmHg depending on study;  2.0-fold higher risk) 
and diabetes mellitus (irrespective of severity, duration and quality of glycemic control; 1.7-
fold higher risk) increased stroke risk.9  SPAF and AFI were part of the original historical trials 
of stroke prevention in patients with AF, and the stroke risk factors were derived from the 
non-warfarin arms of these cohorts; however, these trials randomized <10% of patients Ре
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screened, and many common stroke risk factors were not systematically looked for, nor 
recorded. 
 
In the Stroke in AF Working Group, clinical heart failure was not found to be an independent 
risk factor for stroke development.9  One  reason  may be a discrepancy in definitions of 
heart failure between studies, whether defined as heart failure per se, recent congestive 
heart failure, severe-to-moderate systolic dysfunction, fractional shortening ≤25%,  assessed 
via echocardiography, etc.  Data about stroke risk associated with female gender and 
coronary heart diseases as potential risk factors were also not consistent  between studies.9 
 
A more recent systematic review of stroke risk factors in AF found that the best evidence 
was available for prior stroke or TIA (risk ratio 2.86), hypertension (risk ratio 2.27), ageing 
(risk ratio 1.46 per decade increase), structural heart disease (risk ratio 2.0) and diabetes 
(risk ratio 1.62). Female sex (risk ratio 1.67), vascular disease (risk ratio 2.61) and heart 
failure (risk ratio 1.85) were also independent predictors of stroke in about one third of 
included studies.17 
 
Other strong contemporary evidence comes from the Swedish Atrial Fibrillation cohort study 
(n=90490, approximately 1.5 years follow-up, 7334 thromboembolic events), where 
peripheral artery disease (22% risk increase), myocardial infarction (9% risk increase), 
coronary artery bypass graft (19% risk increase), peripheral artery disease (22% risk 
increase), any vascular disease (14% risk increase), female gender (17% risk increase), 
intracranial haemorrhage (49% risk increase) and kidney failure (16% risk increase) were 
identified as independent predictors of thromboembolic events (stroke, TIA, systemic Ре
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emboli). The prognostic value of arterial hypertension, diabetes mellitus, age and previous 
stroke was confirmed, while heart failure defined as just ‘history of’ was not an independent 
stroke risk factor.18 
 
Of note, type of AF (paroxysmal or non-paroxysmal) still confers a similar risk for stroke. For 
example, in the Stockholm Cohort of Atrial Fibrillation, stroke incidence did not differ 
between paroxysmal and chronic AF (26 and 29 events per 1000 patient/years, respectively), 
however, the appearance of paroxysmal AF doubled stroke incidence in the general 
population.19 
 
CHADS2 score 
The CHADS2 score (Table 1) is one of the simplest and commonly used stroke risk 
stratification scheme. It was derived  by the combination of stroke risk factors established in 
the AFI and SPAF studies.20  Compared to the AFI and SPAF risk schemes, the original CHADS2 
score validation publication included ‘any history of hypertension’, instead of the SPAF trial 
definition of systolic blood pressure higher than 160 mmHg; ‘age 75 years or older’, instead 
of combination of age 75 years or older plus female sex; and  ‘recent heart failure 
exacerbation’ instead of any history of heart failure.20  CHADS2 is a point system where 2 
points were assigned to a history of prior cerebral ischemia and 1 point was assigned for the 
presence of each of the other risk factors, with a maximum of 6 points in total.  
 
Initial validation of the CHADS2 score was performed in the National Registry of Atrial 
Fibrillation (NRAF) participants who had non-rheumatic AF and were not taking 
anticoagulation therapy at hospital discharge (n=1733).20  A strong relationship was found Ре
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between the CHADS2 score and the adjusted stroke rate (Table 1).
20  The CHADS2 score 
showed the highest performance comparatively to SPAF and AFI schemes.20 C-statistics 
(used to compare the goodness of fit of regression models with the range between 0.5 
[model is not better than chance at making prediction] and 1.0 [perfect prediction with the 
model]) was 0.82; 0.74 and 0.68 for the three schemas, respectively.20  Adjustment for 
aspirin therapy as well as subdivision into low (CHADS2 0-1), moderate (CHADS2 2-3) and high 
(CHADS2 4-6) risk strata did not significantly alter the c-statistic.
20 
 
In the original validation, ‘low risk patients’ for whom antiplatelet treatment was 
recommended was defined as CHADS2 0, while ‘moderate risk’ was defined as CHADS2 1-2, 
and ‘high risk’ as CHADS2>2.
21  This was problematic, since patients with a stroke as their 
only risk factor would be classed as ‘moderate risk’ despite such patients being at the 
highest risk of further stokes.  Subsequent treatments based on the CHADS2 score was 
revised with ‘moderate risk’ being defined as CHADS2=1 and ‘high risk’ as CHADS2 ≥2.
22  
More recent guidelines even recommended oral anticoagulation for those with CHADS2 ≥1.
23 
 
The predictive value of the CHADS2 score was further analyzed in a cohort of 2580 patients 
with nonvalvular AF taking aspirin (207 ischaemic strokes, 4887 patient-years), and 
compared  with the AFI12,13, SPAF11, Framingham10 and ACCP (American College of Chest 
Physicians)24  risk stratification schemes.25  The CHADS2 score was best in identifying high risk 
patients (5.3 strokes per 100 patient-years) whereas high  risk patients identified by other 
schemes had 3.0 to 4.2 strokes per 100 patient-years. Discrimination of the low risk patients 
did not differ between stratification schemes (0.5 to 1.4 strokes per 100 patient-years of 
therapy).25  A good  performance of the CHADS2 score in the identification of high risk 
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patients was also confirmed in the community-based cohort study from the Olmsted County 
(n=2720, 4.4 years follow-up, 350 thromboembolic events).26 
 
In contrast,  application of the five stratification schemes including CHADS2 to the ATRIA 
cohort (n=13559, six year follow-up, 685 thromboembolic events) showed poor 
discriminative ability (c-statistics 0.58) with only a minor increase in thromboembolism rate 
with corresponding increase in the risk category. A significant proportion of patients without 
thromboembolism appeared within the high risk category and conversely, many patients 
with thromboembolic events were found in the low risk stratum.  Broadly similar c-statistics 
were obtained for other scores.27  The latter was confirmed in the Swedish Atrial Fibrillation 
Cohort Study where the CHADS2 score had a c-statistic of 0.66 and other risk scores ranged 
0.58-0.67.18  Low performance of the CHADS2  score was also seen in the systematic review 
of several studies but wide heterogeneity was evident.28 
 
In summary, the CHADS2 score manages well in identifying high  risk patients but provides, 
ambiguous results in those at low  or moderate stroke  risk.29  Thus, the CHADS2 score has 
been subject to criticism for several reasons: first,  its low discrimination ability for patients 
at low risk of stroke development; second, important independent stroke and 
thromboembolism risk factors were not included; and third, discrepancy between the 
original validation and further applications in guidelines and ‘real world’ cohorts.30,31 
 
CHA2DS2-VASc score 
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To overcome some of the limitations of the CHADS2 score, the CHA2DS2-VASc (see Table 2 for 
acronym) score has been proposed, giving extra weight to age ≥75, since this is a major 
driver of stroke risk, and including additional risk factors such as age 65-74, female gender 
and vascular disease.6,32 
 
The CHA2DS2-VASc score was proposed as a risk factor based approach, which de-
emphasised the artificial low, moderate and high risk classification.  This score assigns 2 
points to prior stroke, TIA, or thromboembolism, and older age [≥75 years]), as the major 
risk factors. Other clinically relevant non-major risk factors are assigned 1 point each:  heart 
failure (moderate to severe systolic left ventricular dysfunction, deﬁned arbitrarily as left 
ventricular ejection fraction ≤40%, or recent decompensated heart failure requiring 
hospitalisation), hypertension, diabetes, female sex, age 65–74 years, and vascular disease 
(e.g., myocardial infarction, complex aortic plaque and peripheral artery disease).6,32 
 
With the introduction of the CHA2DS2-VASc score, categorization of the AF patients 
improved significantly with respect to selecting patients at low risk of stroke (essentially, a 
CHA2DS2-VASc=0 in males or CHA2DS2-VASc=1 in females).
4,5,33 These are the patients with 
lone AF without structural heart disease and aged  <65 years. Such ‘truly low-risk’  patients 
do not need any antithrombotic therapy, and the subsequent step would be that all other AF 
patients, those with ≥1 stroke risk factor require appropriate antithrombotic prophylaxis, 
which is essentially oral anticoagulation.3 
 
The advantages of the CHA2DS2-VASc score were clearly demonstrated in a retrospective 
analysis performed in the Danish nationwide cohort study which involved 19444 patients Ре
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with CHADS2 score=0, i.e., low  risk patients. When their stroke risk was substratified 
according to the CHA2DS2-VASc score, those with a CHADS2 score=0 had stroke rates ranging 
from 0.8%/year to 3.2%/year.34 For the 28132 subjects with the CHADS2 score=1, the stroke 
rate based on substratification according to the CHA2DS2-VASc score  was as high as 8.18 % 
at one year.34 
 
Since a CHADS2 score=0 (or 1) can confer significant stroke risk, the benefits of oral 
anticoagulation in comparison to antiplatelet or no antithrombotic therapy in these patients 
are evident.35,36  Indeed, a lower stroke incidence was found in patients taking warfarin 
compared to those taking aspirin (4.2% vs. 12.9%) without any difference in the incidence of 
major bleeding.35  This was consistent with another study by Gorin et al who observed a 2.4 
higher risk of stroke in the group of non-anticoagulated  patients with CHADS2 score=1.
36 
 
What is the impact of ‘non-CHADS2’ risk factors?  Peripheral artery disease taken separately 
was associated with an even higher risk than myocardial infarction (93% vs. 12% increase in 
risk).37  In the Loire Valley Atrial Fibrillation Project (n=6438), vascular disease when added to 
the CHADS2 score improved stratification of patients (net reclassification improvement 
0.4).38  In a Taiwanese nationwide database analysis (n=7920) there was positive link 
between peripheral artery disease and ischaemic  stroke development (odds ratio 1.81).39 
 
The value of female gender as a risk factor for stroke in AF was reported previously.17  In  the 
Swedish Atrial Fibrillation cohort female gender remained an independent predictor (14%  
increase in risk).39  This was also evident in a population-based cohort from the Quebec, 
Canada (14% increase in risk)41 and a Danish nationwide cohort (20% increase in risk).42  An Ре
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age differential was evident, as differences in stroke rate with females  became evident only 
if associated with other risk factors.  
 
The risk of stroke rises from age 65 upwards, and each ten years of aging results in 1.5-fold 
increase in risk.43  Stroke/thromboembolic rate increased significantly from 0.23 to 2.05 and 
3.99 for <65, 65-74 and ≥75 age categories, respectively.38  On average, a 3-fold and 5-fold 
increase in risk of stroke was observed for the latter two age categories when compared 
with those younger than 65.18 
 
The controversy of heart failure as risk factor of stroke has already been pointed out above. 
The CHA2DS2-VASc score uses heart failure defined as moderate to severe left ventricular 
systolic dysfunction or recent heart failure exacerbation that requires hospitalization 
(independently of reduced or preserved systolic function).3  The distinction about preserved 
systolic function is of particular importance in patients with AF as about half of such patients 
belong to this category.44 Prognostic significance of heart failure with preserved systolic 
function in AF has limited evidence, but in the Loire Valley Atrial Fibrillation Project  there 
were no differences in rates of stroke/thromboembolism between patients with heart 
failure with preserved ejection fraction, compared to those with heart failure and reduced 
ejection fraction.45  Another study found a 3.3-fold higher rate (20.6% vs. 6.7%) of ischaemic 
stroke and 5.5-fold of death (27.2% vs. 2.0%) in patients with AF and heart failure with 
preserved ejection fraction compared to those with AF only after 3 years of follow-up.46 
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Since initial derivation and validation of the CHA2DS2-VASc score in the Euro  Heart Survey on 
AF32, its performance has also been confirmed in the several cohorts, including large real-
world cohorts (Table 3).18,26,47-49 
 
Interestingly, all contemporary risk stratification schemes can be used for stroke prediction 
even in the non-AF population equally well (c-statistics ranging 0.658 to 0.728) as shown in 
the Chi-Shan Community Cohort Study (n=3524, approximately  16 years of follow-up).49 
 
In summary, the performance of the CHA2DS2-VASc score for predicting those at high risk of 
stroke/thromboembolism was comparable with other contemporary risk stratification 
schemes as the 8th ACCP51, NICE52 and modified CHADS2
32.  The CHA2DS2-VASc score is 
currently recommended by the European guidelines on AF management as the main scheme 
to assess patient’s stroke risk3  because of its’ ability to  identify low risk patients as this was 
the principal group that do not need anticogulation.33 
 
R2CHADS2 score 
The R2CHADS2 score (Table 4) was suggested based on an ancillary  analysis of the ROCKET 
AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K 
antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation)  cohort 
(n=14264).53  The score incorporates the components of the CHADS2 score and also assigns 2 
points for creatinine clearance <60 mL/min.53 
 
Development of the R2CHADS2 score was driven by the knowledge that AF and kidney 
dysfunction coexist commonly and both increase the risk of stroke. For example, in one Ре
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cohort of stable anticoagulated AF patients (n=978) during 2 years of follow-up a low 
estimated glomerular filtration rate (eGFR) was associated with combined end-point (stroke, 
acute coronary syndrome, acute heart failure);  there was a 42% increase in risk with each 30 
ml/min/1.73 m2  eGFR decrease.54 
 
The R2CHADS2 score had a c-statistic 0.587 and did not differ from the CHA2DS2-VASc and the 
CHADS2 schemes (0.578 and 0.575, respectively) in the ROCKET AF cohort.
53  It was not 
better in predicting of thromboembolic events than the above-mentioned schemes in 
patients after catheter ablation of AF in the cohort from the Leipzig Heart Center AF Ablation 
Registry (n= 2069, 1.5 years of follow-up) as well.55 
 
The R2CHADS2 score has many limitations which may affect its performance, for example, 
derivation from a selected anticoagulated clinical trial cohort, which excluded patients with 
the creatinine clearance <30 mL/min and included those with a high risk of stroke 
development, etc.56  The latter is contradictory to current recommendations to firstly 
identify low risk patients. Moreover, kidney dysfunction is known to be independently 
associated with female gender, advanced age, heart failure (i.e., components of CHADS2), 
that eventually may lead to a reduction of the predictive value of the R2CHADS2 score.
57 
Thus, as renal dysfunction in general results in poorer prognosis of AF patients, the 
independent predictive value of the R2CHADS2 score for stroke requires further validation 
with inclusion of patients with the full spectrum of stages of chronic kidney disease. 
 
QStroke score Ре
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The QStroke score was developed based on analysis of data from general practices in 
England and Wales (QResearch database, derivation cohort n=3.5 million, 77578 strokes, 
validation cohort n=1.9 million, 38404 strokes).58  This score is relatively complex and 
includes 17 variables (Table 5). Importantly, patients with history of stroke or TIA, were 
excluded from this study.  Separate calculation for males and females are performed and 
QStroke can be used in both AF and non-AF populations.58  The QStroke score was composed 
of risk factors from the QRISK2 score that was developed for the purpose of predicting 
cardiovascular disease risk.59,60 
 
In the validation cohort, the QStroke scheme did slightly better than the CHA2DS2-VASc and 
CHADS2 scores in predicting stroke risk but these differences were not significant. For 
example, c-statistics for females were 0.65, 0.62 and 0.61 for three schemes, respectively.58 
Thus, despite high representativeness, duration of the follow-up, size of derivation and 
validation cohorts, and general availability of data which are necessary for risk calculation, 
there are no major advantages in favor of the substantially more complex QStroke score. On 
the contrary, it represents a shift towards a more complex and less practical approach to 
individual stroke risk calculation. 
 
The ATRIA stroke risk score 
The ATRIA stroke risk score (hereinafter referred to as the ATRIA score) is the newest stroke 
risk stratification scheme proposed. This score was derived from ATRIA cohort.27  Only those 
patients who were not on anticoagulation (median time out of warfarin 2.4 years) were 
included in the current analysis (n=10927).61  The ATRIA score represents a point-based 
stratification scheme (Table 5) separately for patients without prior stroke (i.e., primary Ре
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prevention) and those with history of stroke (i.e., secondary prevention).61  An ATRIA score 
of 0 to 5 points corresponds to low risk (event rates of <1% per year), 6 points equates to 
moderate risk (1-2% event rate) and 7 to 15 points indicates high risk (event rate ≥2% per 
year). 
 
The ATRIA score was validated in the ATRIA–Cardiovascular Research Network (CVRN) cohort 
(n=25306, 496 thromboembolic events). C-statistics were 0.70 for the ATRIA score, 0.66 for 
CHADS2 and 0.68 for CHA2DS2-VASc, with net reclassification improvement of about 25% 
with the ATRIA score if all thromboembolic events were considered or 33% for severe 
thromboembolic events only. Of note, the ATRIA score particularly focused on the severe 
thromboembolic events  (defined as Rankin score ≥3 at discharge or death within 30 days 
after the event), as the predictive ability of the scheme was higher (c-statistic up to 0.76) for 
this group than for all patients with thromboembolic events.61 
 
In summary, the ATRIA score is more complex than both the CHA2DS2-VASc and the CHADS2  
scores and emphasizes the importance of severe thromboembolic conditions, leading to 
death or significant disability, and deemphasizes other events. Such an approach may result 
in under-treatment of AF patients with oral anticoagulants particularly those with non-
severe thromboembolism with further much more devastating outcomes. 
 
 
Bleeding risk assessment in atrial fibrillation 
Increased risk of haemorrhage, particularly intracranial bleeding, is a downside of 
thromboprophylaxis with oral anticoagulation. The annual incidence of the anticoagulant-Ре
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associated intracranial bleeding increased from 0.8 to 4.4 per 100,000 people during the 
nineties, with increasing use of warfarin.62  A recent meta-analysis including 16 randomized 
controlled trials (61 563 patient-years of follow-up) and 31 observational studies (484 241 
patient-years of the follow-up) confirmed the high rate of major bleeding in the 
anticoagulated population (approximately 2 per 100 patient-years).63 
 
An informed approach to assessing bleeding risk is needed.  However, many risk factors for 
bleeding are also stroke risk factors.  Many risk factors for bleeding are reversible, for 
example, uncontrolled blood pressure, labile INRs (if on warfarin), concomitant use of aspirin 
or NSAIDs, alcohol excess, etc.  Various bleeding risk assessment scores have been 
developed, but not all of them target the AF population and have been appropriately 
validated.64 
 
It is clear that bleeding risk is not equal in all patients taking oral anticoagulants. Also, 
bleeding events may vary in severity. Many current bleeding risk schemes evaluate major 
bleeding, that is, those involving critical sites (intracranial, retroperitoneal, intraspinal, 
intraocular, pericardial, atraumatic intra-articular haemorrhage) which may be potentially 
fatal. There are also laboratory indices of major bleeding like a drop of hemoglobin more 
than 2 g/dl or need to transfuse 2 or more units of packed red blood cells.65 
 
Some stroke and bleeding risk factors are broadly similar, for example, advanced age, female 
gender, arterial hypertension, congestive heart failure, etc. – and these are usually non-
modifiable.66 Of note, bleeding risk should not be considered as a contraindication or a 
reason to discontinue treatment with the oral anticoagulants, as the reduction in stroke risk Ре
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on anticoagulation usually far exceeds the elevation in bleeding risk. For example, in the 
cohort of 13559 patients with nonvalvular AF, the net clinical benefit of warfarin,  balancing 
stroke against serious bleeding, was 0.68% for the whole studied population but even higher 
(>2%) for patients with a history of stroke or in the elderly, i.e., those with high stroke risk.67  
This was in line with the results from the Swedish Atrial Fibrillation Cohort Study, in which 
only the low risk patients with a CHA2DS2-VASc=0, were found not to benefit from warfarin 
therapy.68 
 
HEMORR2HAGES score 
The HEMORR2HAGES score (see Table 7 for acronym) was derived from known bleeding risk 
factors from the National Registry of Atrial Fibrillation (n=3791, 162 events recorded).69 It 
assigned one point for each risk factor but two points for previous bleeding, and denoted a 
score of ≥4 as high risk. Based on the original analysis, the HEMORR2HAGES score had better 
predictive ability (c-statistic 0.67) than older prediction schemes.69 However, this score is not 
easily applied to routine clinical practice, due in part to the necessity of genetic testing.  
 
HAS-BLED score 
The HAS-BLED score (see Table 8 for acronym) was first derived  and validated in the Euro 
Heart Survey in AF cohort (n=3978, 1-year follow-up, 1.5% of major bleedings) with inclusion 
of previously established bleeding risk factors.70  Hypertension was defined as  uncontrolled 
hypertension (systolic blood pressure >160 mmHg). Abnormal renal function refers to serum 
creatinine ≥200 μmol/l, chronic dialysis or kidney transplantation; abnormal liver function 
refers to chronic liver disease or increase of biochemical indices of liver function (>2-fold for 
bilirubin, >3-fold for aminotransferases, alkaline phosphatase). Labile INR is defined as time Ре
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in the therapeutic range of <60% and is only used if patient is  taking warfarin or a vitamin K 
antagonist. The elderly criterion denotes age>65 years, although in reality this refers to 
‘biological age’ that is, extreme frailty and poor physical state. Concomitant drugs include 
those that enhance bleeding risk with warfarin (e.g.,  antiplatelets or non-steroidal anti-
inflammatory drugs). Alcohol abuse or excess implies for more than (say) 20 units per week. 
The resultant HAS-BLED score is a sum of one point for the presence of each risk factor (for 
kidney/liver dysfunction and drugs/alcohol separately), with a score of ≥3 used as criterion 
for high risk.70 
 
Table 9 shows the performance of the simple HAS-BLED score versus other bleeding risk 
assessment schemas in AF patients. The HAS-BLED score is also predictive of intracranial 
bleeding72, and has been used to predict bleeding with non-warfarin anticoagulants73.  HAS-
BLED is also validated in AF and non-AF patients74, as well as for predicting bleeding in those 
undergoing bridging75 and percutaneous coronary interventions76-79. 
 
The ATRIA bleeding risk score  
The ATRIA bleeding risk score (hereinafter referred to as ATRIA bleeding score; see Table 10)  
defines high risk as score  of 5 to 10 points.80  The c-statistic for predicting risk of major 
bleeding was 0.74 in the ATRIA cohort and net reclassification improvement, when 
compared with the HEMORR2HAGES score, was 28.9%.
80  The ATRIA score was derived from  
anticoagulated (and INR-stabilized) patients, whereas onset of treatment with oral 
anticoagulants is known to be associated with higher risk of bleeding events.81  There was 
also concern about the definition employed for  certain factors, used for generation of the 
ATRIA score, compared to other scores. For example, the ATRIA score included history of Ре
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hypertension rather than uncontrolled hypertension, age cut-off 75 years rather 65 years 
and of particular note, concomitant aspirin use was not considered a risk factor for bleeding. 
The poorer performance of the ATRIA score and its’ inability to predict intracranial bleeding 
in comparison with the HAS-BLED scheme was observed in several validation cohorts (Table 
9).72,82  
 
In summary, the HAS-BLED score is the best tool for bleeding prediction in patients with AF 
requiring or receiving  anticoagulation to date, and current guidelines reflect this.3  There are 
a few other bleeding risk schemes in addition to  HAS-BLED, but they are less-well validated 
or perform less well.64 
 
Combination stroke and bleeding risk assessment scores 
As many of the risk factors for stroke and bleeding in AF overlap intentions to develop 
combined stroke and bleeding risk assessment tool look attractive and obvious. Two 
combined scores for stroke/thromboembolism/bleeding that offer good discriminatory and 
predictive performance were developed and validated in the vitamin K antagonist arm of the 
AMADEUS trial (Table 11).83  The composite end point ‘stroke/thromboembolism or major 
bleeding’ was predicted by age, previous stroke/TIA, aspirin use, and time in therapeutic 
range. Predictors for another composite end point ‘stroke, systemic or venous embolism, 
myocardial infarction, cardiovascular death, or major bleeding’ were the same but also  
included left ventricular dysfunction.83 
 
In the recent Loire Valley Atrial Fibrillation Project analysis, their composite model included 
previous heart failure, age >75, age >65, diabetes mellitus, stroke, vascular disease, liver Ре
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and/or renal impairment, previous bleeding and labile INR (i.e. risk factors from the HAS-
BLED and CHA2DS2-VASc scores) and was tested for several end-points.
84  Both studies failed 
to improve prediction of stroke and bleeding events beyond existing individual stroke or 
bleeding scores, and thereby currently recommended stroke and bleeding stratification 
schemes which allow greater usability and a more individualized balancing of risks should be 
continued. 
 
Other scores 
The importance of appropriate dose adjustment of warfarin with good INR control has been 
highlighted many times.3,5  Labile INR was found to be associated both with increased risk of 
stroke and major bleeding.64,70,85-88 The individual mean time in therapeutic range (TTR) is 
used to evaluate quality of warfarin treatment management.  
 
Overall survival in AF patients increases starting from a TTR of 40% compared to non-
anticoagulated patients, but the risk of stroke is reduced only if TTR is above 70%.85  In 
27458 patients taking warfarin from the UK General Practice Database, adhering to 70% 
threshold resulted in 79% reduction in risk of stroke when compared with patients with a 
TTR<30%.86 With the increased use of novel oral anticoagulants the problem of poor 
anticoagulation control is likely to be partly solved5,33,87 as they do not depend upon INR 
control but high quality anticoagulation control for warfarin patients remains of paramount  
importance88 and an important issue in the decision making process of who’s likely to fare 
well with being started on warfarin rather than a novel oral anticoagulant89. 
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The SAMe-TT2R2 score (see Table 12 for acronym) was proposed based on an analysis of the 
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, in order to 
help to identify which AF patients will achieve high TTR with the warfarin treatment (SAMe-
TT2R2 score 0-1), and those who are at risk of suboptimal anticoagulation control (SAMe-
TT2R2 score ≥2).
90  Additional validation of this score in a subsequent ‘real  world’ validation 
cohort of AF patients, demonstrated that high SAMe-TT2R2 scores (>2) were predictive of 
labile INRs, and consequently, serious bleeding and thromboembolism.91 
 
Conclusion 
Many stroke and bleeding risk stratification scores are available for clinicians to use in 
everyday management of AF patients. A balance is needed between simplicity and 
practicality, versus predictive value. For stroke risk, the CHA2DS2-VASc score has gained wide 
acceptance, and stratifies the majority of AF patients into high (and moderate) risk group 
that requires anticoagulation.  The HAS-BLED score appears to be the best for bleeding risk 
assessment. Guidelines have evolved to reflect the new evidence base on how we can 
improve  our  individualised assessment of AF patients. 
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Table 1. Stroke risk stratification with the CHADS2  score
20 
Risk factor Score CHADS2 
score 
Stroke 
rate, % 
Congestive heart failure (recent) 1 0 1.9 
Hypertension(history of) 1 1 2.8 
Age ≥75 years 1 2 4.0 
Diabetes mellitus 1 3 5.9 
Stroke/transient ischaemic attack (TIA) 2 4 8.5 
  5 12.5 
  6 18.2 
Maximum score 6   
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Table 2. Stroke risk stratification with the CHA2DS2-VASc scheme
32 
Risk factor Score CHA2DS2-VASc 
score 
Thrombo-
embolic  
event rate44 
Congestive heart failure/LV 
dysfunction 
1 0 0 
Hypertension 1 1 1.3 
Age ≥75 years 2 2 2.2 
Diabetes mellitus 1 3 3.2 
Stroke/TIA/TE 2 4 4.0 
Vascular disease (prior MI, 
PAD, or aortic plaque) 
1 5 6.7 
Aged 65–74 years 1 6 9.8 
Sex category (i.e. female 
gender) 
1 7 9.6 
  8 6.7 
  9 15.2 
Maximum score 9   
 
LV, left ventricular; MI, myocardial infarction; PAD, peripheral artery disease; TIA/TE, 
transient ischemic attack/thromboembolism 
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Table 3. Predictive ability of different risk stratification schemes, as expressed by the c-
statistic, in patients without anticoagulant treatment 
Study cohort 
No of 
patients 
Stroke / 
thrombo-
embolism 
rate (per 
100 
patient-
years) 
C-statistic (95% confidence interval)a 
CHA2DS2-
VASc score 
CHADS2 
score 
(revised) 
CHADS2 
score 
(classical) 
Euro Heart Survey 
on Atrial 
Fibrillation32 
1 084 2.3 0.606 (0.513-
0.699) 
0.586 (0.477-
0.695) 
0.561 (0.450-
0.672) 
Swedish Atrial 
Fibrillation cohort 
study18 
90 490 6.2 0.56 (0.56–
0.57) 
0.61 (0.61–
0.62) 
0.64 (0.64–
0.65) 
United Kingdom 
General Practice 
Research 
Database48 
79 844 0.5, low; 
1.1, 
moderate; 
4.6, high 
risk b 
0.60 (0.59–
0.61) c 
0.63 (0.61–
0.65) c 
0.65 (0.63–
0.67) c 
Nationwide 
register of AF 
patients in 
Denmark47 
73 538 1.67 0.850 (0.829 
to 0.871) d 
0.722 (0.694 
to 0.748) d 
 
Community-based 
cohort  study from 
Olmsted County, 
Minnesota26 
2 720 2.94 0.58 (0.57-
0.58) 
0.65 (0.63–
0.67) 
0.65 (0.63–
0.68) 
SPORTIF III and V 
cohorts49 e 
7329 1.63 0.647 (0.613, 
0.678) 
0.637 (0.607-
0.674) 
0.637 (0.607-
0.674) 
 
a for categorization into 3 groups (low, moderate and high risk) in all studies, apart from 
Swedish Atrial Fibrillation cohort study, in which ‘low risk’ versus ‘intermediate or high risk’ 
were analysed; b according to the CHA2DS2-VASc score; 
c for strokes recorded by the general 
practitioners or in hospital; d at 1 year follow-up, rising to 0.888 (0.875-0.900) and 0.812 
(0.796-0.827) at 10 years follow-up for the CHA2DS2-VASc and CHADS2 scores, respectively; 
e 
anticoagulated trial cohorts 
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Table 4. Stroke risk stratification with the R2CHADS2 scheme
53 
 
Risk factor Score 
Renal dysfunction (i.e. creatinine clearance <60 
mL/min) 
2 
Congestive heart failure (recent) 1 
Hypertension 1 
Age ≥75 years 1 
Diabetes mellitus 1 
Stroke/transient ischaemic attack 2 
Maximum score 8 
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Table 5. Stroke risk stratification with the QStrokea,b scheme58 
Risk factor Score 
Age (at entry) Range 25-84 
Sex Separate models for women 
and men 
Treated hypertension (diagnosis of hypertension and ≥1 
current prescription for ≥1 antihypertensive) 
Yes/No 
Type 1 diabetes Yes/No 
Type 2 diabetes Yes/No 
Atrial fibrillation Yes/No 
Congestive cardiac failure Yes/No 
Coronary heart disease Yes/No 
Self-assigned ethnicity (White/not recorded, Indian, 
Pakistani, Bangladeshi, Other Asian, Black Caribbean, 
Black African,  Chinese, other/mixed) 
9 categories  
Townsend deprivation score Continuous 
Smoking  status(non-smoker, ex-smoker, light smoker 
(<10 cigarettes/day), moderate smoker (10-19 
cigarettes/day), heavy smoker (≥20 cigarettes/day) 
5 categories  
Systolic blood pressure Continuous 
Cholesterol:HDL ratio Continuous 
Body mass index Continuous 
Family history of coronary disease (in first degree relative 
<60 years of age) 
Yes/No 
Rheumatoid arthritis Yes/No 
Chronic renal disease Yes/No 
Valvular heart disease Yes/No 
Maximum score 99% 
a Importantly previous stroke or transient ischaemic attack was not included 
b Designed for use in primary care as it requires an algorithm to calculate the QStroke score 
which can be incorporated into existing software 
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Table 6. Stroke risk stratification with the ATRIA score61 
Risk factor Score without prior stroke Score with prior stroke 
Age   
≥85 6 9 
75 to 84 5 7 
65 to 74 3 7 
<65 0 8 
Female 1 1 
Diabetes 1 1 
Congestive heart failure 1 1 
Hypertension 1 1 
Proteinuria 1 1 
eGFR<45 or ESRD 1 1 
Maximum score 12 15 
 
eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease 
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Table 7. Bleeding risk stratification with the HEMORR2HAGES score
69 
 
Risk factor Score 
Hepatic or renal disease 1 
Ethanol abuse  1 
Malignancy 1 
Older (aged ≥75 years) 1 
Reduced platelet count or function 1 
Rebleeding risk 2 
Hypertension(uncontrolled) 1 
Anaemia 1 
Genetic factors (CYP2C9 single nucleotide 
polymorphism) 
1 
Excessive fall risk 1 
Stroke 1 
Maximum score 12 
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Table 8. Bleeding risk stratification with the HAS-BLED score70 
Risk factors Score 
Hypertension (systolic blood pressure >160 mm Hg) 1 
Abnormal renal and / or  liver function 1 or 2 
Stroke 1 
Bleeding tendency or predisposition 1 
Labile INRs (if on warfarin) 1 
Age (e.g.,>65, frail condition) 1 
Drugs (e.g., concomitant antiplatelet  or NSAIDs) or 
alcohol excess/abuse 
1 or 2 
Maximum score 9 
 
INR, international normalized ratio; NSAIDs, non-steroidal anti-inflammatory drugs 
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Table 9. Predictive ability of different bleeding risk stratification schemes, as expressed by 
the c-statistic, in patients with anticoagulant treatment 
 
AMADEUS, Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in 
Patients With Atrial Fibrillation 
a HAS-BLED score outperformed the ATRIA bleeding score, when they were collapsed into 
binary groups, i.e. high risk vs. low plus moderate risk for major bleeding (c-statistic 0.68 
[0.65-0.71] versus 0.59 [0.55-0.62], respectively). 
  
Study cohort 
No of 
anticoagulated 
patients 
Major 
bleeding 
(per 100 
patient-
years ) 
C-statistic (95% confidence interval) 
HAS-BLED 
score 
HEMORR2HAGES 
score 
ATRIA 
bleeding 
score 
Euro Heart Survey on 
Atrial Fibrillation70 
1772 1.56 0.69 (0.59-
0.80) 
0.64 (0.53-0.75) - 
Swedish Atrial 
Fibrillation cohort 
study18 
48599 1.9 0.61 (0.59–
0.62) 
0.63 (0.61–0.64) - 
Nationwide register of 
AF patients in 
Denmark71 
44771 5.27 0.795 (0.759–
0.829) 
0.771 (0.733–
0.806) 
- 
ATRIA cohort80 3063 1.4 - 0.71 (0.69–0.73) 0.74 (0.72–
0.76) 
Roldán et al82 937 3.2 0.71 (0.68-
0.74)a 
- 0.68 (0.65-
0.71) 
AMADEUS trial cohort72 
b 
2293 1.4 0.65 (0.56–
0.73) 
0.60 (0.51–0.69) 0.61 (0.51–
0.70) 
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Table 10. Bleeding risk stratification with the ATRIA score80 
Risk factor  Score 
Anaemia a 3 
Severe renal disease (eGFR <30 ml/min or 
dialysis-dependent) 
3 
Age ≥75years 2 
Prior haemorrhage 1 
Diagnosed hypertension 1 
Maximum score 10 
 
a haemoglobin <13 g/dl in men and <12 g/dl in women and/or thrombocytopenia (platelet 
count <90,000) 
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Table 11. Composite stroke and bleeding risk scores83 
Composite score 1 Composite score 2 
Combination of stroke/thromboembolism  
or major bleeding 
Combination of stroke, systemic or venous 
embolism, myocardial infarction, 
cardiovascular death, or major bleeding 
(Age x 0.05) + (Previous stroke/TIA x 0.6) + 
(Concomitant aspirin x 0.9) – (TTR x 1.8) 
(Age x 0.05) + (Previous stroke/TIA x 0.6) + 
(Concomitant aspirin x 0.7) + (LV dysfunction 
x 0.6) – (TTR x 1.4) 
 
LV, left ventricular;  TIA, transient ischemic attack; TTR, time in therapeutic range 
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Table 12. Quality of anticoagulation control assessment with the SAMe-TT2R2  score
90 
Risk factors Score 
Sex category (i.e. female gender) 1 
Age <60 years 1 
Medical history (≥2 of the following: hypertension, DM, CAD/MI, PAD, 
CHF, previous stroke, pulmonary, hepatic or renal disease) 
1 
Treatment with interacting drugs (e.g., amiodarone) 1 
Tobacco use (within 2 years) 2 
Race (i.e. non-caucasian) 2 
Maximum score 8 
 
CAD, coronary artery disease;  CHF, congestive heart failure; DM, diabetes mellitus; MI, 
myocardial infarction; PAD, peripheral artery disease 
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